JP2000517194A - モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異 - Google Patents
モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異Info
- Publication number
- JP2000517194A JP2000517194A JP10515749A JP51574998A JP2000517194A JP 2000517194 A JP2000517194 A JP 2000517194A JP 10515749 A JP10515749 A JP 10515749A JP 51574998 A JP51574998 A JP 51574998A JP 2000517194 A JP2000517194 A JP 2000517194A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- vaccine
- nucleotide
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 223
- 230000035772 mutation Effects 0.000 title claims abstract description 84
- 108700039691 Genetic Promoter Regions Proteins 0.000 title claims abstract description 39
- 241000711513 Mononegavirales Species 0.000 title claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 title claims description 125
- 229960005486 vaccine Drugs 0.000 claims abstract description 123
- 230000002238 attenuated effect Effects 0.000 claims abstract description 59
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims abstract description 18
- 241001493065 dsRNA viruses Species 0.000 claims abstract description 18
- 239000002773 nucleotide Substances 0.000 claims description 146
- 125000003729 nucleotide group Chemical group 0.000 claims description 143
- 241000712079 Measles morbillivirus Species 0.000 claims description 74
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 235000018102 proteins Nutrition 0.000 claims description 65
- 238000013518 transcription Methods 0.000 claims description 63
- 230000035897 transcription Effects 0.000 claims description 62
- 150000001413 amino acids Chemical class 0.000 claims description 49
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 229940024606 amino acid Drugs 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 40
- 230000010076 replication Effects 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 241000712003 Human respirovirus 3 Species 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 15
- 239000004473 Threonine Substances 0.000 claims description 15
- 239000004475 Arginine Substances 0.000 claims description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 14
- 241000711902 Pneumovirus Species 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- 235000003704 aspartic acid Nutrition 0.000 claims description 10
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 10
- 210000003501 vero cell Anatomy 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- 241000711502 Paramyxovirinae Species 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- 241000711504 Paramyxoviridae Species 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 241000711950 Filoviridae Species 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 6
- 241000711920 Human orthopneumovirus Species 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- 241000712045 Morbillivirus Species 0.000 claims description 5
- 241000711904 Pneumoviridae Species 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 241000711931 Rhabdoviridae Species 0.000 claims description 3
- 230000004186 co-expression Effects 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 241001533467 Rubulavirus Species 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 46
- 230000008859 change Effects 0.000 description 36
- 108020004999 messenger RNA Proteins 0.000 description 32
- 230000003612 virological effect Effects 0.000 description 31
- 101150062031 L gene Proteins 0.000 description 29
- 201000005505 Measles Diseases 0.000 description 28
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000002845 virion Anatomy 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 241000712083 Canine morbillivirus Species 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000012300 Sequence Analysis Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000001018 virulence Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940125575 vaccine candidate Drugs 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000030500 lower respiratory tract disease Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000711404 Avian avulavirus 1 Species 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 101150046652 M2 gene Proteins 0.000 description 4
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710144128 Non-structural protein 2 Proteins 0.000 description 4
- 101710199667 Nuclear export protein Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101150084044 P gene Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229940041323 measles vaccine Drugs 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003212 purines Chemical class 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000282552 Chlorocebus aethiops Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000726306 Irus Species 0.000 description 3
- 229940124862 Measles virus vaccine Drugs 0.000 description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 3
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- 101710132653 Protein M2 Proteins 0.000 description 3
- 102000004389 Ribonucleoproteins Human genes 0.000 description 3
- 108010081734 Ribonucleoproteins Proteins 0.000 description 3
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000004545 gene duplication Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000011479 upper respiratory tract disease Diseases 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241001455610 Ephemerovirus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101150082239 G gene Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000006257 Rinderpest Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 244000309457 enveloped RNA virus Species 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 101150061325 mv gene Proteins 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005029 transcription elongation Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- AXXVSCRPHPIDIW-UHFFFAOYSA-N 7h-purin-6-amine;7h-purine Chemical compound C1=NC=C2NC=NC2=N1.NC1=NC=NC2=C1NC=N2 AXXVSCRPHPIDIW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000711895 Bovine orthopneumovirus Species 0.000 description 1
- 241000712005 Bovine respirovirus 3 Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241001502545 Dolphin morbillivirus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 229940127030 Foster Drugs 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 101000584515 Homo sapiens Synaptic vesicle glycoprotein 2B Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000190596 Latino mammarenavirus Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150067196 NSI gene Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010056332 Panencephalitis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000010357 RNA editing Methods 0.000 description 1
- 230000026279 RNA modification Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 101150107578 SH gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710200413 Small hydrophobic protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100030700 Synaptic vesicle glycoprotein 2B Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 101710165741 Virion-associated protein Proteins 0.000 description 1
- 241000701815 Xipapillomavirus 1 Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 102220351054 c.122G>A Human genes 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical group [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000017156 mRNA modification Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- MWNFNXOAMKFJAE-UHFFFAOYSA-N methanamine;silver Chemical compound [Ag].NC MWNFNXOAMKFJAE-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 3’ゲノムプロモーター領域内に少なくとも一つの弱毒性突然変異を有 し、かつRNAポリメラーゼ遺伝子内に少なくとも一つの弱毒性突然変異を有す る目モノネガビラレス(Mononegavirales)の単離され、組換え 法により作成され、弱毒化された、非分節、マイナス鎖−センス、一本鎖RNA ウイルス。 2. ウイルスが科パラミクソウイルス科(Paramyxoviridae )からのものである、請求の範囲1のウイルス。 3. ウイルスが亜科パラミクソビリナエ(Paramyxovirinae )からのものである請求の範囲2のウイルス。 4. ウイルスが属モルビリウイルス(Morbillivirus)からの ものである請求の範囲3のウイルス。 5. ウイルスが麻疹ウイルスである、請求の範囲4のウイルス。 6. (a)3’ゲノムプロモーター領域内の少なくとも一つの弱毒性突然変 異が、ヌクレオチド26(A→T)、ヌクレオチド42(A→TもしくはA→C )、およびヌクレオチド96(G→A)からなる群より選択され、この場合これ らのヌクレオチドはプラス鎖、アンチゲノム、メッセージセンスとして表され; そして (b)RNAポリメラーゼ遺伝子中の少なくとも一つの弱毒性突然変異 が、残基331(イソロイシン→スレオニン)、1409(アラニン→スレオニ ン)、1624(スレオニン→アラニン)、1649(アルギニン→メチオニン )、1717(アスパラギン酸→アラニン)、1936(ヒスチジン→チロシン )、2074(グルタミン→アルギニ ン)、および2114(アルギニン→リシン)からなる群より選択されるアミノ 酸の変化を生じるヌクレオチド変化からなる群より選択される: 請求の範囲5の麻疹ウイルス。 7. ウイルスが属パラミクソウイルス(Paramyxovirus)から のものである、請求の範囲3のウイルス。 8. ウイルスがヒトパラインフルエンザウイルス タイプ3(PIV−3) である、請求の範囲7のウイルス。 9. (a)3’ゲノムプロモーター領域内の少なくとも一つの弱毒性突然変 異が、ヌクレオチド23(T→C)、ヌクレオチド24(C→T)、ヌクレオチ ド28(G→T)、およびヌクレオチド45(T→A)からなる群より選択され 、この場合これらのヌクレオチドはプラス鎖、アンヂゲノム、メッセージセンス として表され;そして (b)RNAポリメラーゼ遺伝子中の少なくとも一つの弱毒性突然変異 が、残基942(チロシン→ヒスチジン)、992(ロイシン→フェニルアラニ ン)、および1558(スレオニン→イソロイシン)からなる群より選択される アミノ酸の変化を生じるヌクレオチド変化からなる群より選択される: 請求の範囲8のPIV−3。 10. ウイルスが属ルブラウイルス(Rubulavirus)からのもので ある、請求の範囲3のウイルス。 11. ウイルスが亜科ニューモビリナエ(Pneumovirinae)から のものである、請求の範囲2のウイルス。 12. ウイルスが属ニューモウイルス(Pneumovirus)か らのものである、請求の範囲11のウイルス。 13. ウイルスがヒトRSウイルス(RSV)亜群Bである、請求の範囲12 のウイルス。 14. (a)3’ゲノムプロモーター領域内の少なくとも一つの弱毒性突然変 異が、ヌクレオチド4(C→G)、およびヌクレオチド6〜11の複数のAの配 列(stretch)内の追加的Aの挿入からなる群より選択され、この場合こ れらのヌクレオチドはプラス鎖、アンチゲノム、メッセージセンスとして表され ;そして (b)RNAポリメラーゼ遺伝子中の少なくとも一つの弱毒性突然変異 が、残基353(アルギニンン→リシン)、451(リシン→アルギニン)、1 229(アスパラギン酸→アスパラギン)、2029(スレオニン→イソロイシ ン)、および2050(アスパラギン→アスパラギン酸)からなる群より選択さ れるアミノ酸の変化を生じるヌクレオチド変化からなる群より選択される: 請求の範囲13のウイルス。 15. ウイルスが科ラブドウイルス科(Rhabdoviridae)からの ものである、請求の範囲1のウイルス。 16. ウイルスが科フィロウイルス科(Filoviridae)からのもの である、請求の範囲1のウイルス。 17. 請求の範囲1に記載の目モノネガビラレス(Mononegavira les)の単離され、組換え法により作成され、弱毒化された、非分節、マイナ ス鎖−センス、一本鎖RNAウイルスおよび生理学的に許容される担体を含むワ クチン。 18. 請求の範囲5に記載の麻疹ウイルスおよび生理学的に許容され る担体を含む請求の範囲17のワクチン。 19. 請求の範囲6に記載の麻疹ウイルスおよび生理学的に許容される担体を 含む請求の範囲18のワクチン。 20. 請求の範囲8に記載のPIV−3および生理学的に許容される担体を含 む請求の範囲17のワクチン。 21. 請求の範囲9に記載のPIV−3および生理学的に許容される担体を含 む請求の範囲20のワクチン。 22. 請求の範囲13に記載のRSV亜群Bおよび生理学的に許容される担体 を含む請求の範囲17のワクチン。 23. 請求の範囲14に記載のRSV亜群Bおよび生理学的に許容される担体 を含む請求の範囲22のワクチン。 24. 目モノネガビラレス(Mononegavirales)の非分節、マ イナス鎖−センス、一本鎖RNAウイルスに対する防御を誘導するために、ある 個体を免疫化するための、その個体に請求の範囲17のワクチンを投与すること を含む方法。 25. ワクチンが請求の範囲18のワクチンである、請求の範囲24の方法。 26. ワクチンが請求の範囲19のワクチンである、請求の範囲25の方法。 27. ワクチンが請求の範囲20のワクチンである、請求の範囲24の方法。 28. ワクチンが請求の範囲21のワクチンである、請求の範囲27の方法。 29. ワクチンが請求の範囲22のワクチンである、請求の範囲24 の方法。 30. ワクチンが請求の範囲23のワクチンである、請求の範囲29の方法。 31. 1977野生型株(配列番号3)、1983野生型株(配列番号5)( この場合、ヌクレオチド2499はGもしくはCである)、モンテフィオーレ( Montefiore)野生型株(配列番号7)、Rubeovax(商標)ワ クチン株(配列番号9)(この場合、ヌクレオチド2143はTもしくはCであ る)、モラテン(Moraten)ワクチン株(配列番号11)、シュワルツ( Schwarz)ワクチン株(配列番号11)(この場合、ヌクレオチド491 7はCであり、そしてヌクレオチド4924はCである)、およびザグレブ(Z agreb)ワクチン株(配列番号13)、ならびにそれらの相補性ゲノム配列 から選択される、プラス鎖、アンチゲノム、メッセージセンスの麻疹ウイルス配 列を含む単離された核酸分子。 32. アカゲザル(rhesus)胎仔肺細胞内で生育させたcp45ワクチ ン株(配列番号19)およびベロ(Vero)細胞内で生育させたcp45ワク チン株(配列番号21)、ならびにそれらの相補性ゲノム配列からなる群より選 択されるプラス鎖、アンチゲノム、メッセージセンスのPIV−3配列を含む単 離された核酸分子。 33. 3’ゲノムプロモーター領域内に少なくとも一つの弱毒性突然変異を有 し、かつRNAポリメラーゼ遺伝子内に少なくとも一つの弱毒性突然変異を有す る目モノネガビラレス(Mononegavirales)の非分節、マイナス 鎖−センス、一本鎖RNAウイルスのゲノムもしくはアンチゲノムをコードする 単離された核酸分子を含む転写ベク ターを、カプシド形成、転写、および複製に必要なトランス−作用性蛋白質をコ ードし、少なくとも一つの単離された核酸分子を含む少なくとも一つの発現ベク ターと共に含み、発現の際に感染性弱毒化ウイルスが産生される組成物。 34. 転写ベクターが、請求の範囲5に記載の麻疹ウイルスをコードする単離 された核酸分子を含み、かつ少なくとも一つの発現ベクターが、トランス−作用 性蛋白質N、P、およびLをコードする少なくとも一つの単離された核酸分子を 含む、請求の範囲33の組成物。 35. 転写ベクターが、請求の範囲6に記載の麻疹ウイルスをコードする単離 された核酸分子を含む、請求の範囲34の組成物。 36. 転写ベクターが、請求の範囲8に記載のPIV−3をコードする単離さ れた核酸分子を含み、かつ少なくとも一つの発現ベクターが、トランス−作用性 蛋白質NP、P、およびLをコードする少なくとも一つの単離された核酸分子を 含む、請求の範囲33の組成物。 37. 転写ベクターが、請求の範囲9に記載のPIV−3をコードする単離さ れた核酸分子を含む、請求の範囲36の組成物。 38. 転写ベクターが、請求の範囲13に記載のRSV亜群Bをコードする単 離された核酸分子を含み、かつ少なくとも一つの発現ベクターが、トランス−作 用性蛋白質N、P、L、およびM2をコードする少なくとも一つの単離された核 酸分子を含む、請求の範囲33の組成物。 39. 転写ベクターが、請求の範囲14に記載のRSV亜群Bをコードする単 離された核酸分子を含む、請求の範囲38の組成物。 40. 目モノネガビラレス(Mononegavirales)の感染性、弱 毒化、非分節、マイナス鎖−センス、一本鎖RNAウイルスを 産生するための、宿主細胞を、請求の範囲33の少なくとも2つのベクターで形 質転換もしくはトランスフェクトし、そしてその宿主細胞を、感染性、弱毒化ウ イルスを産生するようにそれらのベクターの同時発現を可能にする条件下で培養 することを含む方法。 41. ウイルスが、請求の範囲5の麻疹ウイルスである、請求の範囲40の方 法。 42. ウイルスが、請求の範囲6の麻疹ウイルスである、請求の範囲41の方 法。 43. ウイルスが、請求の範囲8のPIV−3である、請求の範囲40の方法 。 44. ウイルスが、請求の範囲9のPIV−3である、請求の範囲43の方法 。 45. ウイルスが、請求の範囲13のRSV亜群Bである、請求の範囲40の 方法。 46. ウイルスが、請求の範囲14のRSV亜群Bである、請求の範囲45の 方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2682396P | 1996-09-27 | 1996-09-27 | |
US60/026,823 | 1996-09-27 | ||
PCT/US1997/016718 WO1998013501A2 (en) | 1996-09-27 | 1997-09-19 | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000517194A true JP2000517194A (ja) | 2000-12-26 |
Family
ID=21833976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10515749A Ceased JP2000517194A (ja) | 1996-09-27 | 1997-09-19 | モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0932684A2 (ja) |
JP (1) | JP2000517194A (ja) |
KR (1) | KR20000048628A (ja) |
CN (1) | CN1232504A (ja) |
AU (1) | AU4427897A (ja) |
BR (1) | BR9712138A (ja) |
CA (1) | CA2265554A1 (ja) |
WO (1) | WO1998013501A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524053A (ja) * | 2003-03-28 | 2006-10-26 | メッドイミューン バクシーンズ、インコーポレイティド | 呼吸器合胞体ウイルスサブグループb株9320に関連する組成物および方法 |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
US6410023B1 (en) | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
BR9812232A (pt) * | 1997-09-19 | 2000-07-18 | American Cyanamid Co | Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico |
BR9909076A (pt) * | 1998-03-26 | 2000-12-05 | American Cyanamid Co | Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b |
WO1999063064A1 (en) * | 1998-06-03 | 1999-12-09 | American Cyanamid Company | Novel methods for rescue of rna viruses |
ATE384126T1 (de) | 1998-06-12 | 2008-02-15 | Sinai School Medicine | Interferon induzierende genetisch veränderte attenuierte viren |
DK1086207T3 (da) | 1998-06-12 | 2007-05-29 | Sinai School Medicine | Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
WO2001077394A1 (en) | 2000-04-10 | 2001-10-18 | Mount Sinai School Of Medicine Of New York University | Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents |
CN1298738C (zh) | 2000-06-23 | 2007-02-07 | 惠氏控股有限公司 | 修饰的麻疹病毒v蛋白 |
US7361496B1 (en) | 2000-08-02 | 2008-04-22 | Wyeth | Rescue of mumps virus from cDNA |
UA93981C2 (ru) | 2001-01-19 | 2011-03-25 | Вироновативе Б.B. | Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих |
US8715922B2 (en) | 2001-01-19 | 2014-05-06 | ViroNovative | Virus causing respiratory tract illness in susceptible mammals |
WO2003072720A2 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
CN103540568A (zh) | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒*** |
DK1375670T3 (da) | 2002-06-20 | 2013-09-23 | Pasteur Institut | Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger |
ES2330309T3 (es) * | 2002-06-20 | 2009-12-09 | Institut Pasteur | Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas. |
CA2432738A1 (en) * | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
US7704720B2 (en) | 2003-04-25 | 2010-04-27 | Medimmune, Llc | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
EP1633312A4 (en) | 2003-06-16 | 2012-09-26 | Medimmune Llc | INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS |
AU2004308328B2 (en) | 2003-12-23 | 2009-06-04 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
CA2568020C (en) | 2004-05-25 | 2015-04-07 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
BRPI0511776B1 (pt) | 2004-06-01 | 2016-11-29 | Sinai School Medicine | vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica |
US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
CA2600730C (en) | 2005-03-08 | 2014-11-25 | Medimmune, Inc. | Influenza hemagglutinin and neuraminidase variants |
US7790434B2 (en) | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
KR20080025171A (ko) | 2005-06-21 | 2008-03-19 | 메드이뮨 백신즈 인코포레이티드 | 이종성 프로테아제를 발현시키기 위한 방법 및 조성물 |
US9387242B2 (en) | 2005-12-02 | 2016-07-12 | Icahn School Of Medicine At Mount Sinai | Chimeric viruses presenting non-native surface proteins and uses thereof |
JP5491173B2 (ja) | 2006-04-19 | 2014-05-14 | メディミューン,エルエルシー | イヌ細胞中でマイナス鎖ウイルスrnaを発現させるための方法および組成物 |
EP2049662A4 (en) | 2006-07-21 | 2009-12-30 | Medimmune Llc | METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS |
JP2010500034A (ja) | 2006-08-09 | 2010-01-07 | メッドイミューン バクシーンズ,インコーポレイティド | インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体 |
EP2099903A4 (en) | 2006-12-22 | 2010-07-28 | Penn State Res Found | MODIFIED POLYMERASES AND WEIGHTENED VIRUSES AND METHOD FOR THEIR USE |
CA2690196A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
CN102149405A (zh) | 2008-07-11 | 2011-08-10 | 米迪缪尼股份有限公司 | 流感血凝素和神经氨酸酶变体 |
NZ614064A (en) | 2008-11-05 | 2015-04-24 | Wyeth Llc | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease |
US8591881B2 (en) | 2009-02-05 | 2013-11-26 | Mount Sinai School Of Medicine | Chimeric Newcastle disease viruses and uses thereof |
AU2010213966B2 (en) | 2009-02-12 | 2015-01-22 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
US9217157B2 (en) | 2009-07-27 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Recombinant influenza viruses and uses thereof |
JP5845180B2 (ja) | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルス及びそれらの使用 |
JP2013526849A (ja) | 2010-03-30 | 2013-06-27 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
EP2420242A1 (en) | 2010-08-20 | 2012-02-22 | Lauer, Ulrich M. | Oncolytic measles virus |
CN103906843B (zh) * | 2011-06-08 | 2016-12-07 | 维什瓦斯·乔希 | 双质粒哺乳动物表达*** |
WO2013046216A2 (en) * | 2011-06-08 | 2013-04-04 | JOSHI Vishwas | A simple two plasmid mammalian expression system for production of recombinant proteins and viruses |
SG11201400743VA (en) | 2011-09-20 | 2014-04-28 | Sinai School Medicine | Influenza virus vaccines and uses thereof |
EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
AU2013362935B2 (en) | 2012-12-18 | 2018-10-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
AU2014241843B2 (en) | 2013-03-14 | 2019-05-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
WO2014159960A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
KR102407019B1 (ko) | 2014-02-27 | 2022-06-08 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 결합 방법 |
AU2016209032A1 (en) | 2015-01-23 | 2017-08-10 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
EP3261664A1 (en) | 2015-02-26 | 2018-01-03 | Boehringer Ingelheim Vetmedica GmbH | Bivalent swine influenza virus vaccine |
JP7048482B2 (ja) | 2015-08-03 | 2022-04-05 | アメリカ合衆国 | Brachyury欠失変異体、Brachyury欠失変異体をコードする非酵母ベクター、及びそれらの使用 |
EP3337504A1 (en) | 2015-08-20 | 2018-06-27 | University of Rochester | Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus |
WO2017031408A1 (en) | 2015-08-20 | 2017-02-23 | University Of Rochester | Single-cycle virus for the development of canine influenza vaccines |
US10973903B2 (en) | 2015-08-20 | 2021-04-13 | University Of Rochester | NS1 truncated virus for the development of canine influenza vaccines |
MX2018014955A (es) | 2016-06-03 | 2019-05-13 | Univ Rochester | Vacunas atenuadas vivas del virus de la influenza equina. |
JP7237344B2 (ja) | 2016-06-15 | 2023-03-13 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルス血球凝集素タンパク質及びその使用 |
WO2018187706A2 (en) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
AR114410A1 (es) | 2018-02-27 | 2020-09-02 | Univ Rochester | Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
CA3130781A1 (en) | 2019-02-27 | 2020-09-03 | University Of Rochester | Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses |
US11103576B1 (en) | 2020-06-15 | 2021-08-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Measles virus vaccine expressing SARS-COV-2 protein(s) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7007491A (en) * | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
JP3045581B2 (ja) * | 1991-10-14 | 2000-05-29 | 社団法人北里研究所 | 麻疹ワクチンウイルス株同定方法 |
EP0636172B1 (en) * | 1992-04-14 | 2005-08-17 | The Mount Sinai School of Medicine of the City University of New York | Genetically engineered attenuated viruses |
TW275632B (ja) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co | |
IL105456A (en) * | 1992-04-21 | 1996-12-05 | American Home Prod | Vaccines of attenuated respiratory syncytial virus |
PT702085E (pt) * | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
-
1997
- 1997-09-19 JP JP10515749A patent/JP2000517194A/ja not_active Ceased
- 1997-09-19 WO PCT/US1997/016718 patent/WO1998013501A2/en not_active Application Discontinuation
- 1997-09-19 KR KR1019990702569A patent/KR20000048628A/ko not_active Application Discontinuation
- 1997-09-19 CA CA002265554A patent/CA2265554A1/en not_active Abandoned
- 1997-09-19 EP EP97942613A patent/EP0932684A2/en not_active Withdrawn
- 1997-09-19 CN CN97198321A patent/CN1232504A/zh active Pending
- 1997-09-19 AU AU44278/97A patent/AU4427897A/en not_active Abandoned
- 1997-09-19 BR BR9712138-0A patent/BR9712138A/pt not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006524053A (ja) * | 2003-03-28 | 2006-10-26 | メッドイミューン バクシーンズ、インコーポレイティド | 呼吸器合胞体ウイルスサブグループb株9320に関連する組成物および方法 |
JP4783726B2 (ja) * | 2003-03-28 | 2011-09-28 | メディミューン,エルエルシー | 呼吸器合胞体ウイルスサブグループb株9320に関連する組成物および方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0932684A2 (en) | 1999-08-04 |
WO1998013501A2 (en) | 1998-04-02 |
CA2265554A1 (en) | 1998-04-02 |
BR9712138A (pt) | 2000-01-18 |
KR20000048628A (ko) | 2000-07-25 |
WO1998013501A3 (en) | 1998-08-13 |
AU4427897A (en) | 1998-04-17 |
CN1232504A (zh) | 1999-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000517194A (ja) | モノネガビラレス(Mononegavirales)と称される目のウイルスにおける弱毒化の原因となる3’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異 | |
KR100885325B1 (ko) | 변형된 모빌리바이러스 v 단백질 | |
JP2001517448A (ja) | 弱毒化呼吸合胞体ウイルス | |
KR100658491B1 (ko) | 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산 | |
Vainionpää et al. | Biology of parainfluenza viruses | |
CA2304932C (en) | Recombinant rsv virus expression systems and vaccines | |
AU2020203460B2 (en) | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization | |
CN1871355B (zh) | 从cDNA中回收非节段性负链RNA病毒的改进方法 | |
AU2009202359A1 (en) | Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens | |
Skiadopoulos et al. | Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins | |
CN1384877B (zh) | 从cDNA拯救腮腺炎病毒 | |
JP2007524372A (ja) | 組換えヒトメタニューモウイルスおよびその使用 | |
US7465574B2 (en) | Recombinant RSV virus expression systems and vaccines | |
US6830748B1 (en) | Recombinant RSV virus expression systems and vaccines | |
US20120308602A1 (en) | Recombinant RSV Virus Expression Systems And Vaccines | |
JP2002507408A (ja) | 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループbの弱毒化の原因である突然変異 | |
JP2023529836A (ja) | 生弱毒化呼吸器合胞体ウイルス | |
AU2003200297B2 (en) | Recombinant RSV virus expression systems and vaccines | |
AU2004237877A1 (en) | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales | |
AU2006200619B2 (en) | Recombinant RSV virus expression systems and vaccines | |
Dhanasekaran | Reverse genetics of avian metapneumovirus | |
Longhurst | Genetic variability of measles virus during propagation in cultured cells | |
AU2008201113A1 (en) | Recombinant RSV virus expression systems and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040901 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080108 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080414 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080610 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080722 |